Background Medicinal cannabinoids, including medicinal cannabis and pharmaceutical
cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and …

The concept of schizophrenia only covers the 30% poor outcome fraction of a much broader
multidimensional psychotic syndrome, yet paradoxically has become the dominant prism …

Background The risk of individuals having adverse effects from drug use (eg, alcohol)
generally depends on the frequency of use and potency of the drug used. We aimed to …

Associations between cannabis use and psychotic outcomes are consistently reported, but
establishing causality from observational designs can be problematic. We review the …

BackgroundThe psychosis-proneness–persistence–impairment model of psychotic disorder
incorporates notions of both phenomenological and temporal continuity (persistence) of …

Cannabis is a complex plant, with major compounds such as delta-9-tetrahydrocannabinol
and cannabidiol, which have opposing effects. The discovery of its compounds has led to …

Epidemiological evidence demonstrates that cannabis use is associated with an increased
risk of psychotic outcomes, and confirms a dose‐response relationship between the level of …

Background We conducted a systematic review of incidence rates in England over a sixty-
year period to determine the extent to which rates varied along accepted (age, sex) and less …

For over two decades, cannabis, commonly known as marijuana, has been the most widely
used illicit drug by young people in high-income countries, and has recently become …

Cannabis is the most commonly used illicit drug worldwide, with~ 5 million daily users
worldwide. Emerging evidence supports a number of associations between cannabis and …